Brizel D M, Rosner G L, Prosnitz L R, Dewhirst M W
Department of Radiation Oncology, Duke University Comprehensive Cancer Center, Durham, NC 27710, USA.
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1121-5. doi: 10.1016/0360-3016(95)00106-9.
The validity of tumor pO2 measurement as a predictive outcome assay depends upon demonstrating that intrapatient pO2 variation is less than interpatient variation. No consensus exists regarding the appropriate distance between individual measurements. This distance could affect the calculation of the hypoxic fraction (% pO2s < 5 mm Hg) and the assessment of intra/interpatient heterogeneity. This study was performed to evaluate tumor oxygenation and to assess the effects of two different measurement intervals on pO2 heterogeneity in three different sets of patients.
Fifteen patients with soft tissue sarcoma, nine patients with cervical carcinoma, and eight patients with squamous carcinoma metastatic to lymph nodes underwent pretreatment polarographic pO2 measurements. Two grossly distinct sites were studied in each tumor, and 2-3 linear tracks were measured at each site. Track lengths varied from 20-36 mm. Distance between measured points was either 0.7-0.8 mm or 0.4 mm. Mean pO2, median pO2, and hypoxic fraction were calculated for each track. Data for each patient were also averaged across all tracks obtained for that patient. Track-specific data were used to evaluate intrapatient variation. The range of average values for each patient was used to assess interpatient heterogeneity. The ratio of these measures provided an assessment of within- vs. between-patient heterogeneity.
The median number of pO2 measurements/patient was 200 (range: 88-356). The average length of hypoxic regions varied from 4.5-5.6 mm. Median tumor pO2s for the cervix, lymph node, and sarcoma patients were 4.5 mm Hg, 12.6 mm Hg, and 18.0 mm Hg, respectively (p = 0.07). Median hypoxic fractions were 0.61, 0.36, and 0.31, respectively (p = 0.07). Intrapatient heterogeneity was less than interpatient heterogeneity for all parameters in all patients, except for mean pO2 for the cervix patients measured at 0.7-mm increments (1.51). Assessment of oxygenation was not affected by the distance between samples.
Heterogeneity of tumor oxygenation within tumors is less than that between tumors. Both 0.4 mm and 0.7-0.8 mm sampling increments provide similar data. Longer term follow-up of large numbers of uniformly treated patients is required to define the value of tumor oxygen measurement as a predictor of treatment outcome.
肿瘤pO2测量作为一种预测结果分析方法的有效性取决于能否证明患者体内pO2的变化小于患者之间的变化。对于各个测量点之间的合适距离尚无共识。该距离可能会影响缺氧分数(% pO2<5 mmHg)的计算以及患者内/患者间异质性的评估。本研究旨在评估肿瘤氧合情况,并评估两种不同测量间隔对三组不同患者pO2异质性的影响。
15例软组织肉瘤患者、9例宫颈癌患者和8例淋巴结转移鳞状癌患者接受了治疗前极谱法pO2测量。在每个肿瘤中研究两个明显不同的部位,每个部位测量2-3条线性轨迹。轨迹长度在20-36 mm之间。测量点之间的距离为0.7-0.8 mm或0.4 mm。计算每条轨迹的平均pO2、中位数pO2和缺氧分数。每个患者的数据也对该患者获得的所有轨迹进行平均。特定轨迹的数据用于评估患者内的变化。每个患者平均值的范围用于评估患者间的异质性。这些测量值的比率用于评估患者内与患者间的异质性。
每位患者pO2测量的中位数为200(范围:88-356)。缺氧区域的平均长度在4.5-5.6 mm之间。宫颈癌、淋巴结和肉瘤患者的肿瘤pO2中位数分别为4.5 mmHg、12.6 mmHg和18.0 mmHg(p = 0.07)。缺氧分数中位数分别为0.61、0.36和0.31(p = 0.07)。除了以0.7 mm增量测量的宫颈癌患者的平均pO2(1.51)外,所有患者所有参数的患者内异质性均小于患者间异质性。氧合评估不受样本之间距离的影响。
肿瘤内肿瘤氧合的异质性小于肿瘤之间的异质性。0.4 mm和0.7-0.8 mm的采样增量提供了相似的数据。需要对大量接受统一治疗的患者进行长期随访,以确定肿瘤氧测量作为治疗结果预测指标的价值。